Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | AMY1A | P0DUB6 | 4/20 | 0.46 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5249670 | 0.80 | MAPT (0.56) | TDP1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL8539529 | 0.80 | GPR35 (0.49) | HTTTDP1PKMKMT2AMEN1 | |
| SCHEMBL3132515 | 0.78 | LMNA (0.49) | HTTTDP1AMY1APKMKMT2A | |
| SCHEMBL31463535 | 0.78 | AMY1A (0.48) | HTTTDP1AMY1AL3MBTL1KMT2A | |
| SCHEMBL5747525 | 0.78 | MEN1 (0.46) | TDP1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL8540776 | 0.78 | AMY1A (0.48) | HTTTDP1AMY1AL3MBTL1KMT2A | |
| SCHEMBL8536128 | 0.78 | NPC1 (0.43) | HTTTDP1AMY1AL3MBTL1KMT2A | |
| SCHEMBL9292469 | 0.77 | NPC1 (0.44) | TDP1L3MBTL1KMT2AMEN1NPC1 | |
| SCHEMBL4055359 | 0.77 | HSD17B10 (0.49) | TDP1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL6003238 | 0.76 | PDE2A (0.55) | HTTSMPD3CDK2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3020717-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2021-12-15 | — | — | EP | disclosed |
| US-9873683-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2018-01-23 | — | — | US | disclosed |
| US-9840497-B2 | — | — | 2017-12-12 | — | — | US | disclosed |
| US-20160244434-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| EP-3020717-A1 | P2X4 RECEPTOR ANTAGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2016-05-18 | — | — | EP | disclosed |
| EP-0857171-A2 | IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-08-12 | — | — | EP | disclosed |
| WO-1997015555-A2 | IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244434-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX1, P2RX7, P2RX2 | HTT 4557/4885TDP1 3094/4885AMY1A 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.